CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...